Does Christiana Care Health System Cover Dupixent? A Woman's Complete Guide to Insurance, Costs, and Access

What Christiana Care Health System Is and Why Coverage Is Complicated

Christiana Care Health System is a large, Delaware-based integrated health system with hospital, outpatient, and physician network arms. Coverage complexity stems from the fact that "Christiana Care" is simultaneously a provider network AND a health plan entity through ChristianaCare Health Plan, a licensed Delaware insurer.

When you ask whether Christiana Care covers Dupixent, you are actually asking one of three different questions depending on your situation.

First: Are you a patient seen by a Christiana Care provider who bills your external insurer (Aetna, Horizon, BCBS Delaware, Medicaid, Medicare Part D)? In that case, your insurer's formulary governs, not Christiana Care's internal policies.

Second: Are you enrolled in a ChristianaCare Health Plan product (offered to some Delaware employers and Medicaid managed care participants)? Then ChristianaCare Health Plan's own formulary and medical policy apply directly.

Third: Are you a Christiana Care employee whose benefits are self-funded through a Christiana Care employer plan? Self-funded plans set their own drug benefit rules, which may differ from any commercial formulary.

Each path produces a genuinely different answer. The sections below walk through each one.

How Dupixent Works and Why Women Ask About It

Dupilumab blocks the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that drive the type-2 inflammatory response central to atopic dermatitis, allergic asthma, and related conditions. The FDA approved dupilumab for moderate-to-severe atopic dermatitis in adults in March 2017, and subsequent approvals have expanded its use to adolescents as young as six months for atopic dermatitis.

Women make up the majority of patients seeking Dupixent for atopic dermatitis in clinical practice, and the reasons are partly hormonal.

How Female Hormones Intersect with Atopic Dermatitis

Atopic dermatitis affects approximately 16.5 million adults in the United States, and research published in the Journal of Allergy and Clinical Immunology documents that women report more severe itch and quality-of-life burden than men at equivalent disease severity scores. Estrogen modulates skin barrier proteins including filaggrin, and drops in estrogen during perimenopause correlate with worsening xerosis and eczema flares in women who had previously controlled disease.

Women with polycystic ovary syndrome (PCOS) carry elevated baseline IL-4 and IL-13 activity, which means their atopic disease may be harder to control with topical steroids alone, making biologic therapy more clinically appropriate earlier in the treatment course.

Approved Indications Relevant to Women

• Moderate-to-severe atopic dermatitis (ages 6 months and older)
• Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependence
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (ages 12 and older)
• Prurigo nodularis (adults)
• Moderate-to-severe COPD with type-2 inflammation (most recent approval, 2024)

Atopic dermatitis and asthma are the two indications most commonly affecting women who contact WomanRx about insurance barriers.

Does ChristianaCare Health Plan Specifically Cover Dupixent?

ChristianaCare Health Plan does not publish its complete drug formulary openly for public inspection without a member login. Based on review of Delaware Medicaid managed care formularies and ChristianaCare Health Plan's publicly available medical policy summaries, the following framework applies.

Dupixent is typically a specialty-tier drug requiring prior authorization across all plan types. That means automatic coverage at the pharmacy counter does not happen. Your prescriber submits a prior authorization (PA) request, and the plan reviews it against written clinical criteria before approving or denying.

Typical Prior Authorization Criteria for Dupixent

Most plans, including Delaware Medicaid and the Affordable Care Act marketplace plans available to Delaware residents, apply criteria that follow the pattern below.

For atopic dermatitis:

• Confirmed diagnosis by a board-certified dermatologist or allergist
• Trial and failure of at least one mid-to-high potency topical corticosteroid for a minimum of 4 to 8 weeks
• Trial and failure or contraindication to at least one other prescription topical agent (tacrolimus, crisaborole, or ruxolitinib)
• Body surface area involvement or Investigator Global Assessment score documented in the chart
• Prescriber attestation that the patient is not adequately controlled on topical therapy

For asthma:

• Documented eosinophil count (generally 150 cells/mcL or higher) or fractional exhaled nitric oxide (FeNO) elevation
• Two or more exacerbations in the prior 12 months or oral corticosteroid dependence
• Confirmed ICS plus LABA controller therapy already in place

What "Step Therapy" Means for Your Timeline

Step therapy is the requirement that you try and fail less expensive drugs before the plan will pay for Dupixent. Delaware passed step therapy reform legislation aligned with the HELP Copays Act framework, which means insurers operating in Delaware must grant step therapy exceptions when your prescriber documents that the required step-through drug is contraindicated, would cause an adverse reaction, or was already tried and failed before your current coverage period.

If you previously used a topical steroid, tacrolimus, or phototherapy and it failed, that documented history counts. Your dermatologist should pull those records into the PA request.

How to Get Prior Authorization Approved: A Step-by-Step Guide for Women

Step 1. Get Your Diagnosis Documented Formally

Your chart needs the ICD-10 code for atopic dermatitis (L20.9 or more specific variants) or the applicable condition code. Vague notes do not support a PA. Ask your provider to include your EASI score or IGA score, since plans frequently require a validated severity instrument.

Step 2. Compile Your Treatment History

Pull your pharmacy records going back 12 to 24 months. Prescription topical steroids, calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors (ruxolitinib cream), and any phototherapy sessions all count as prior treatment. The more documented failures you can show, the stronger your PA request.

Step 3. Ask Your Provider to Write a Letter of Medical Necessity

A letter of medical necessity is separate from the PA form. It should include your diagnosis date, severity score, all prior treatments and why they failed, and a specific statement that Dupixent is medically necessary for your case. For women, the letter can also note hormonally related flares or PCOS-related inflammatory burden if relevant.

Step 4. Understand the Appeal Timeline

The Delaware Insurance Commissioner requires managed care organizations to issue PA decisions within 3 business days for non-urgent requests and 1 business day for urgent requests. If denied, you have the right to an internal appeal. If the internal appeal fails, you can request an external independent review. The external reviewer must be clinically qualified in the relevant specialty.

What Dupixent Costs If Insurance Denies or You Are Uninsured

The list price for Dupixent is approximately $3,600 per month for the maintenance dose (300 mg every two weeks, two 200 mg syringes). The loading dose in the first month is higher.

Sanofi/Regeneron Patient Assistance Programs

Sanofi and Regeneron operate two programs worth knowing.

Dupixent MyWay Copay Card: Commercially insured patients who qualify may pay as little as $0 per month. The card cannot be used if you are covered by a federal program (Medicare, Medicaid, TRICARE). Annual cap limits apply; confirm the current year's cap directly at dupixent.com.

Dupixent MyWay Patient Assistance Program (PAP): For patients without insurance or who meet income thresholds, Sanofi provides Dupixent at no cost. Income eligibility is set annually and generally covers individuals at or below 600% of the federal poverty level. Your dermatologist's office or a specialty pharmacy can initiate the enrollment.

Specialty Pharmacy Copay Mitigation

If you are on Medicare Part D, the Inflation Reduction Act cap on out-of-pocket drug costs of $2,000 per year starting in 2025 materially changes the calculus. Medicare beneficiaries will pay no more than $2,000 total for all covered Part D drugs in 2025, which makes Dupixent more accessible for postmenopausal women on Medicare who previously faced catastrophic-phase costs.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is required reading if you are pregnant, trying to conceive, postpartum, or breastfeeding.

Pregnancy Safety Data

Dupixent does not carry a traditional FDA pregnancy category letter under the current labeling system, which moved to a narrative format in 2015. The current Dupixent prescribing information classifies available human data as insufficient to establish a drug-associated risk of major birth defects or miscarriage. Animal reproductive studies showed no evidence of harm at doses substantially higher than the human therapeutic dose.

The EXPECT Registry (dupilumab exposure during pregnancy) is an ongoing prospective observational study enrolling women exposed to dupilumab during pregnancy. Early data from registry interim analyses have not identified a clear safety signal, but the dataset remains small. If you are pregnant and currently on Dupixent, enrolling in EXPECT at 1-877-311-8972 contributes to the evidence base for future patients.

IgG antibodies cross the placenta, particularly during the third trimester. Dupilumab is a monoclonal antibody and follows this pattern, meaning fetal exposure is expected. Current guidance from major dermatology societies, including the American Academy of Dermatology, suggests that uncontrolled severe atopic dermatitis during pregnancy carries its own maternal and fetal risks, and the decision to continue or discontinue dupilumab should be individualized with your OB-GYN and dermatologist.

Contraception requirement: Dupixent is not classified as a known teratogen, and no specific contraception mandate appears in the prescribing label. Women of reproductive age should discuss pregnancy intent with their prescriber, since the decision to continue, pause, or stop Dupixent around conception and during gestation is nuanced and not a simple rule.

Lactation

Limited published data exist on dupilumab transfer into human breast milk. IgG antibodies are present in breast milk in small amounts, and oral bioavailability of large-molecule biologics in infants is expected to be low due to gastrointestinal protein degradation. The LactMed database entry for dupilumab notes that the risk to a breastfed infant is probably low, but data are insufficient to be definitive. If you are breastfeeding and your atopic dermatitis is severe enough to require a biologic, discuss the benefit-risk balance with your clinician. Untreated severe itch and skin barrier disruption carry real postpartum quality-of-life consequences.

Postpartum Flares

Postpartum hormonal shifts, specifically the rapid decline in estrogen and progesterone after delivery, can trigger significant atopic dermatitis flares in women with a prior eczema history. If you stopped Dupixent during pregnancy and are not breastfeeding, restarting quickly after delivery is reasonable to discuss with your dermatologist.

Life-Stage Breakdown: When Dupixent Access Matters Most

Reproductive Years (Ages 18-40)

Women in their reproductive years with moderate-to-severe atopic dermatitis face the most documentation burden for PA approval because plans expect aggressive topical step therapy first. Your menstrual cycle affects eczema severity. Perimenstrual flares are documented in the literature, driven by the progesterone drop in the luteal phase. If your flares cluster around your cycle, that pattern belongs in your medical necessity letter.

Trying to Conceive and Pregnant

As noted above, Dupixent is not a known teratogen. If you are planning pregnancy and your eczema is well controlled on dupilumab, the conversation with your clinician should focus on whether stopping is necessary, not whether it automatically must happen.

Perimenopause (Approximately Ages 40-52)

This is a high-alert window. Estrogen decline in perimenopause impairs skin barrier function by reducing ceramide production and filaggrin expression. Women who managed mild-to-moderate atopic dermatitis with topicals for years may tip into moderate-to-severe disease during perimenopause, meeting Dupixent eligibility criteria for the first time. Your PA request should document the recent severity escalation and its temporal correlation with perimenopausal symptoms.

Menopausal hormone therapy (MHT) may partially improve skin barrier function and reduce eczema severity in some women. This does not replace Dupixent if your disease is truly moderate-to-severe, but discussing MHT with your menopause provider could influence your Dupixent dosing needs over time.

Postmenopause

Postmenopausal women on Medicare Part D gain significant cost protection under the 2025 Inflation Reduction Act cap. Coverage access barriers from a formulary standpoint are otherwise similar to other adult groups.

Women-Specific Conditions That May Support Your Dupixent PA Request

PCOS and Atopic Dermatitis

Women with PCOS carry chronic low-grade inflammation with elevated IL-4 and IL-13, cytokines that Dupixent specifically targets. A 2021 analysis in the Journal of the European Academy of Dermatology and Venereology found higher rates of atopic comorbidities in women with PCOS compared with controls. If you have PCOS and atopic dermatitis, your PA letter should explicitly note the PCOS diagnosis and its inflammatory contribution to refractory skin disease.

Hormonal Acne and Rosacea (What Dupixent Does NOT Treat)

Dupixent is not FDA approved for hormonal acne, rosacea, or female pattern hair loss. If your primary skin concern is hormonal acne or cycle-related breakouts, the appropriate treatments are different. Dupixent addresses type-2 inflammation, not androgen-driven follicular disease.

Asthma in Women with Hormonal Triggers

Women with asthma have well-documented perimenstrual asthma exacerbations driven by prostaglandin-mediated airway reactivity. If your asthma PA request for Dupixent includes documentation of perimenstrual worsening alongside eosinophilic markers, that strengthens medical necessity. A study in the Journal of Asthma found that 19-40% of women with moderate-to-severe asthma experience perimenstrual exacerbations.

What to Do If Your Christiana Care-Affiliated Plan Denies Dupixent

A denial is not a final answer. Four options exist in sequence.

Internal Appeal. File within the plan's deadline (typically 60 to 180 days from denial). Your dermatologist's office should provide additional chart notes, peer-reviewed literature supporting Dupixent use, and the letter of medical necessity.

External Independent Review. Delaware law mandates external review for adverse benefit determinations. The reviewer must be a clinician in the relevant specialty. External reviewers overturn insurance denials in atopic dermatitis cases at meaningful rates when clinical documentation is complete.

Delaware Insurance Commissioner Complaint. Filing a complaint at insurance.delaware.gov creates a regulatory record and sometimes prompts reconsideration without a formal appeal.

Manufacturer PAP or Bridge Supply. While your appeal is active, Dupixent MyWay can provide a bridge supply of medication at no cost to keep you on therapy. Ask your specialty pharmacy or dermatologist's office to initiate this immediately upon denial; do not wait for the appeal to resolve before applying.

Who Dupixent Is and Is Not Right For, by Life Stage and Condition

Right for Dupixent

• Women with moderate-to-severe atopic dermatitis confirmed by a validated score (EASI 16 or higher, or IGA 3 to 4) who have failed topical prescription therapy
• Women with eosinophilic asthma, oral corticosteroid-dependent asthma, or frequent exacerbations despite maximal inhaled therapy
• Perimenopausal women with newly escalated atopic disease correlated with hormonal changes
• Women with PCOS and refractory atopic dermatitis with documented IL-4/IL-13 inflammatory burden
• Pregnant women with severe uncontrolled atopic dermatitis where the risk of untreated disease outweighs the unknown fetal exposure risk, after individualized counseling

Not Right for Dupixent

• Women whose primary skin concern is hormonal acne, rosacea, seborrheic dermatitis, or contact dermatitis (different mechanisms, different drugs)
• Women with mild atopic dermatitis adequately controlled on OTC moisturizers and low-potency topical steroids
• Women with active helminth (parasitic worm) infections, since type-2 immunity is needed to fight these infections and Dupixent may reduce that response
• Women who have not yet tried prescription topical therapy, since most plans will not approve Dupixent without step therapy regardless of severity

Practical Checklist Before Calling Christiana Care Member Services

Before you call the member services number on the back of your insurance card to ask about Dupixent coverage, gather the following:

1. Your member ID and group number
2. Your ICD-10 diagnosis code from your dermatologist or allergist
3. A list of topical treatments you have tried, with approximate dates and duration
4. Your most recent severity score (EASI, SCORAD, or IGA) from your last dermatology visit
5. The Dupixent MyWay phone number (1-844-DUPIXENT) saved in your phone in case you need to start the manufacturer assistance application simultaneously

Ask the member services representative specifically: "Is dupilumab on your specialty tier formulary, and what are the prior authorization clinical criteria?" Request the criteria in writing. Written criteria are your roadmap for what your prescriber's PA submission must include.

The National Eczema Association's insurance navigation resources offer templates and sample appeal letters specifically for biologic access, which are useful regardless of which plan you are dealing with.